Volume 35, Issue 1 (3-2024)
Studies in Medical Sciences 2024, 35(1): 19-29 |
Back to browse issues page
Ethics code: (شماره نامه مجوز: 186160/4/1401/6پ مورخ 12/10/1401 و کد اخلاق IR.UMSU.REC.
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rostami Barandouz H, Mohammadzadeh R, Bagheri M. STUDY OF RS4253778 POLYMORPHISM RELATED TO PEROXISOME PROLIFERATOR ALPHA RECEPTOR GENE IN RAPAMYCIN-TREATED KIDNEY TRANSPLANT RECIPIENTS IN WEST AZARBAIJAN PROVINCE (IRAN). Studies in Medical Sciences 2024; 35 (1) :19-29
URL: http://umj.umsu.ac.ir/article-1-6211-en.html
URL: http://umj.umsu.ac.ir/article-1-6211-en.html
Associate Professor of Molecular Biology and Genetics, Cellular and Molecular Research Center, Cellular and Molecular Medicine Research Institute, Urmia University of Medical Sciences, Urmia, Iran , haniyehr158@gmail.com
Abstract: (1267 Views)
Background & Aims: Rapamycin (sirolimus) is one of the immunosuppressive drugs that has a strong immunosuppressive effect and one of the factors that inhibits mTOR. The drug rapamycin is used in the prevention of kidney transplant rejection in kidney transplant recipients. Sirolimus is not only an inhibitor of the target of rapamycin, but also a substrate for cytochrome P450 enzyme subfamilies and for multidrug efflux pumps. The results of recent studies have shown that peroxisomal proliferation activating receptors, as a group of nuclear receptors, have multiple cellular effects and their genetic polymorphisms in connection with other genes play an important role in creating human immune system responses. The aim of this study was to determine the peroxisome proliferator alpha gene polymorphism in kidney transplant recipients treated with rapamycin and healthy controls in West Azerbaijan province (Iran) and compare them with each other.
Materials & Methods: In this case-control study, 40 kidney transplant recipients treated with rapamycin one mg(as case group) and 63 healthy controls as control group were evaluated. Samplings were done in the kidney transplant clinic of Imam Khomeini Hospital (Urmia) under the supervision of a kidney specialist. The salting out method was used to genomic DNA isolation. PCR products were analyzed after enzymatic cleavage with Taq® enzyme. Data were obtained by direct counting of observed alleles and genotypes as well as the total number of samples. Then chi-square test or Fisher's exact test was used to analyze the results in the 2x2 table. The significant difference between the two groups was considered equal to 0.05.
Results: The frequency of homozygous G/G PPARα rs4253778 genotype and heterozygous G/C PPARα rs4253778 genotype observed in the healthy control group of the present study was 40 (63.49%) and 23 (36.51%) respectively. The homozygous C/C PPARα rs4253778 genotype was not observed in the healthy control group. The frequency of homozygous genotype G/G, heterozygous genotype G/C and homozygous genotype C/C in PPAR α rs4253778 Biomarker in the patient group was 29 (72.5%), 9 (22.5%) and 2 (5%) respectively. Comparison of the desired frequencies in the two groups showed that there is no statistically significant difference (P > 0.05). The frequency of G and C alleles in the patient group is 0.84 and 0.16, respectively; and in healthy control it is equal to 0.81 and 0.19 respectively.
Conclusion. In the present study, we concluded that there was no significant relationship between PPARα rs4253778 G>C polymorphism and the use of low concentration of rapamycin. Further study with more samples related to the topic is recommended.
Materials & Methods: In this case-control study, 40 kidney transplant recipients treated with rapamycin one mg(as case group) and 63 healthy controls as control group were evaluated. Samplings were done in the kidney transplant clinic of Imam Khomeini Hospital (Urmia) under the supervision of a kidney specialist. The salting out method was used to genomic DNA isolation. PCR products were analyzed after enzymatic cleavage with Taq® enzyme. Data were obtained by direct counting of observed alleles and genotypes as well as the total number of samples. Then chi-square test or Fisher's exact test was used to analyze the results in the 2x2 table. The significant difference between the two groups was considered equal to 0.05.
Results: The frequency of homozygous G/G PPARα rs4253778 genotype and heterozygous G/C PPARα rs4253778 genotype observed in the healthy control group of the present study was 40 (63.49%) and 23 (36.51%) respectively. The homozygous C/C PPARα rs4253778 genotype was not observed in the healthy control group. The frequency of homozygous genotype G/G, heterozygous genotype G/C and homozygous genotype C/C in PPAR α rs4253778 Biomarker in the patient group was 29 (72.5%), 9 (22.5%) and 2 (5%) respectively. Comparison of the desired frequencies in the two groups showed that there is no statistically significant difference (P > 0.05). The frequency of G and C alleles in the patient group is 0.84 and 0.16, respectively; and in healthy control it is equal to 0.81 and 0.19 respectively.
Conclusion. In the present study, we concluded that there was no significant relationship between PPARα rs4253778 G>C polymorphism and the use of low concentration of rapamycin. Further study with more samples related to the topic is recommended.
References
1. Garcia GG, Harden P, Chapman J.The global role of kidney transplantation. J Nephropathol 2012;1(2):69-76. [DOI:10.5812/nephropathol.7448] [PMID] []
2. Syed A. Akbar, S. Zafar H. JafriMarco A. Amendola, Beatrice L. Madrazo, Riad Salem,, MBA Kostaki G. Bis. Complications of Renal Transplantation. Radiographics 2005;25(5):1335-56. [DOI:10.1148/rg.255045133] [PMID]
3. Pavkov ME, Harding JL, Burrows NR. Trends in hospitalizations for acute kidney injury-United States, 2000-2014. MMWR Morb Mortal Wkly Rep 2018;67(10):289-93. [DOI:10.15585/mmwr.mm6710a2] [PMID] []
4. Kirchhof J, Petrakova L, Brinkhoff A, Benson S, Schmidt J, Unteroberdörster M, et al.Learned immunosuppressive placebo responses in renal transplant patients. Proc Natl Acad Sci U S A 2018;115(16):4223-7. [DOI:10.1073/pnas.1720548115] [PMID] []
5. Hill P, Cross NB, Barnett ANR, Palmer SC, Webster AC. Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients. Cohrane Database SystRev 2017;1(1):CD004759. [DOI:10.1002/14651858.CD004759.pub2] [PMID]
6. Martin ST, Tichy EM, Gabardi S. Belatacept: a novel biologic for maintenance immunosuppression after renal transplantation. Pharmacotherapy 2011;31(4):394-407. [DOI:10.1592/phco.31.4.394] [PMID]
7. Hardinger K, Brennan DC. Kidney transplantation in adults: Maintenance immunosuppressive therapy. UpToDate Waltham, MA, USA; 2020. [Google Scholar]
8. Gonzales HM, McGillicuddy JW, Rohan V, Chandler JL, Nadig SN, Dubay DA, et al. A comprehensive review of the impact of tacrolimus intrapatient variability on clinical outcomes in kidney transplantation. Am J Transplant 2020;20(8):1969-83. [DOI:10.1111/ajt.16002] [PMID]
9. Ma MK, Yung S, Chan TM. mTOR inhibition and kidney diseases. Transplantation 2018;102(2s Suppl 1):s32-s40. [DOI:10.1097/TP.0000000000001729] [PMID]
10. Li D, Zhu H, Luo X, Ge W. PXR haplotype clusters will affect the pharmacokinetics of ciclosporin in Chinese renal transplant recipients. J Pharm Pharmacol 2020;72(2):271-8. [DOI:10.1111/jphp.13206] [PMID]
11. Nguyen LS, Vautier M, Allenbach Y, Zahr N, Benveniste O, Funck-Brentano C, et al. Sirolimus and mTOR inhibitors: a review of side effects and specific management in solid organ transplantation. Drug Saf 2019;42(7):813-25. [DOI:10.1007/s40264-019-00810-9] []
12. Morath C, Arns W, Schweger V, et al. Sirolimus in renal transplantation. Nephrol Dial Transplant 2007; 22suppl(8): viii61-viii65. [DOI:10.1093/ndt/gfm652] [PMID]
13. Cattaneo D, Baldelli S, Perico N. Pharmacogenetics of immunosuppressants: progress, pitfalls and promises. Am J Transplant 2008;8(7):1374-83. [DOI:10.1111/j.1600-6143.2008.02263.x] [PMID]
14. Thomas M, Winter S, Klumpp B, Turpeinen M, Klein K, Schwab M, et al. Peroxisome proliferator-activated receptor alpha, PPARα, directly regulates transcription of cytochrome P450 CYP2C8. Front Pharmacol 2015:6:261. [DOI:10.3389/fphar.2015.00261]
15. Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease.Nature 2000;405(6785):421-4. [DOI:10.1038/35013000] [PMID]
16. Maculewicz E, Mastalerz A, Maciejewska-Skrendo A, Cięszczyk P, Cywińska A, Borecka A, et al. Association between peroxisome proliferator-activated receptor-alpha,-delta and-gamma gene (PPARA, PPARD, PPARG) polymorphisms and overweight parameters in physically active men. Biol Sport 2021;38(4):767-76 [DOI:10.5114/biolsport.2022.109957] [PMID] []
17. Wójtowicz S, Strosznajder AK, Jeżyna M, Strosznajder JB. The novel role of PPAR alpha in the brain: promising target in therapy of Alzheimer's disease and other neurodegenerative disorders. Neurochem Res 2020;45(5):972-88 [DOI:10.1007/s11064-020-02993-5] [PMID] []
18. Sehoon P, Myoungsuk K,Ji Eun K,Kwangsoo K,Minsu P, Yong Chul K,Kwon Wook J,Yon Su K,Hajeong L.Characteristics of Kidney Transplantation recipients over time in South Korea. Korean J Intern Med 2020;35(6):1457-67. [DOI:10.3904/kjim.2019.292] [PMID] []
19. Philip F. Halloran, M.D. Immunosuppressive Drugs for Kidney Transplantation. N Engl J Med 2004;351:2715-29. [DOI:10.1056/NEJMra033540] [PMID]
20. Christians U, Strom T, Zhang YL, et al. Active drug transport of immunosuppressant: new insights for pharmacokinetics and pharmacodynamics.Ther Drug Monit 2006Feb;28(1):39-44. [DOI:10.1097/01.ftd.0000183385.27394.e7] [PMID]
21. Enver A,Barbara M.Gene polymorphisms and transplantation. Curr Opin Immunol 2001;13(5):572-6. [DOI:10.1016/S0952-7915(00)00261-2] [PMID]
22. Golsa Gh,Shahrzad Sh,Ziba F, Shahla Sh,Morteza M. TRANSPLANTATION Sirolimus Dose Requirement in Kidney Transplant Recipients in Iran Iran J Kidney Dis 2020;14(6):510-6. [Google Scholar]
23. Lolita L, Zheng M, Zhang X, Han Z, Tao J, Fei S, et al. The genetic polymorphism of CYP3A4 rs2242480 is associated with sirolimus trough concentrations among adult renal transplant recipients. Curr Drug Metab 2020;21(13):1052-9. [DOI:10.2174/1389200221999201027203401] [PMID]
24. Liu J, Feng D, Kan X, Zheng M, Zhang X, Wang Z, et al. Polymorphisms in the CYP3A5 gene significantly affect the pharmacokinetics of sirolimus after kidney transplantation. Pharmacogenomics 2021;22(14):903-12. [DOI:10.2217/pgs-2021-0083] [PMID]
25. Woillard J-B, Kamar N, Coste S, Rostaing L, Marquet P, Picard N. Effect of CYP3A4* 22, POR* 28, and PPARA rs4253728 on sirolimus in vitro metabolism and trough concentrations in kidney transplant recipients. Clin Chem 2013;59(12):1761-9. [DOI:10.1373/clinchem.2013.204990] [PMID]
26. Eynon N, Ruiz JR, Meckel Y, Moran M, Lucia AMitochondrial biogenesis related endurance genotype score and sports performance in athletes. Mitochondrion 2011;11(1):64-9. [DOI:10.1016/j.mito.2010.07.004] [PMID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
